Table 1. Clinical data and tumour characteristics.
|
Receptor tyrosine kinase mutations
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Group | Number of patients | Mean tumour size (cm) | Ki67 max% | Mitotic rate (/50 hpf) | KIT ex 11 | KIT ex 9 | PDGFRA ex 18 | PDGFRA ex 12 | WT | Mean follow-up (months) |
| Adjuvant imatinib | 23 | 9.4 | 7.0 | 6.2 | del: 8 | dupl: 1 | del: 1 | 0 | 4 | 40 |
| F: 11 | s.d. 7.7 | s.d. 5.0 | s.d. 2.6 | miss: 5 | s.d. 14 | |||||
| M: 12 | range 2–35 | range 2–10 | range 2–10 | dupl: 4 | range 18–62 | |||||
| Historic controls | 48 | 12.3 | 11.7 | 6.8 | del: 20 | 0 | 0 | miss: 1 | 18 | 36 |
| F: 25 | s.d. 7 | s.d. 11.8 | s.d. 3.3 | miss: 6 | s.d. 41 | |||||
| M: 23 | range 3.5–33 | range 0.5–40 | range 2–10 | dupl: 3 | range 2–151 | |||||
Abbreviations: del=deletion; dupl=duplication; ex=exon; F=female; hpf=high power fields; M=male; miss=missense mutation; PDGFRA=platelet-derived growth factor receptor α; WT=wild type (in KIT and PDGFRA).